Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CAPE CORAL, FL · NPI 1144719246
Verified facts
CMS Open Payments records show Michael Anthony Parks, ARNP received $17.17 in general payments during 2025 across 1 reported records.
Dexcom, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.17 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $17.17 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 249 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 228 | 57 |
| Alprazolam | Alprazolam | 187 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 157 | 35 |
| Lisinopril | Lisinopril | 156 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 146 | 23 |
| Tramadol Hcl | Tramadol Hcl | 136 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 123 | 26 |
| Eliquis | Apixaban | 114 | 24 |
| Furosemide | Furosemide | 100 | 35 |
| Trazodone Hcl | Trazodone Hcl | 97 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 14 |
| Jardiance | Empagliflozin | 87 | suppressed |
| Potassium Chloride | Potassium Chloride | 83 | 26 |
| Divalproex Sodium | Divalproex Sodium | 80 | 14 |
| Losartan Potassium | Losartan Potassium | 77 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 21 |
| Sertraline Hcl | Sertraline Hcl | 72 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 27 |
| Lactulose | Lactulose | 70 | 34 |
| Enulose | Lactulose | 69 | 19 |
| Mirtazapine | Mirtazapine | 67 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 64 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 25 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 24 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 58 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 17 |
| Metformin Hcl | Metformin Hcl | 47 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 20 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | 14 |
| Allopurinol | Allopurinol | 40 | suppressed |
| Haloperidol | Haloperidol | 40 | suppressed |
| Omeprazole | Omeprazole | 39 | 22 |
| Incruse Ellipta | Umeclidinium Bromide | 38 | suppressed |
| Lacosamide | Lacosamide | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Famotidine | Famotidine | 35 | 22 |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 29 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 16 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 19 |
| Arnuity Ellipta | Fluticasone Furoate | 24 | suppressed |
| Carvedilol | Carvedilol | 24 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | 13 |
| Invokana | Canagliflozin | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 15 |
| Latanoprost | Latanoprost | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17.17 · 1 records | Dexcom, Inc. | Dexcom G6 Transmitter | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error